272 Stock Overview
A biotechnology company, engages in the development of various biotech drugs based on monoclonal antibody technology in Poland. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
My Notes
Capture your thoughts, links and company narrative
Mabion S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł1.99 |
| 52 Week High | zł4.63 |
| 52 Week Low | zł1.99 |
| Beta | 1.12 |
| 1 Month Change | -25.48% |
| 3 Month Change | -47.53% |
| 1 Year Change | -51.23% |
| 3 Year Change | -85.09% |
| 5 Year Change | n/a |
| Change since IPO | -85.33% |
Recent News & Updates
Recent updates
Shareholder Returns
| 272 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -14.4% | -3.5% | -2.0% |
| 1Y | -51.2% | -14.7% | 6.9% |
Return vs Industry: 272 underperformed the German Biotechs industry which returned -14.7% over the past year.
Return vs Market: 272 underperformed the German Market which returned 6.9% over the past year.
Price Volatility
| 272 volatility | |
|---|---|
| 272 Average Weekly Movement | 7.5% |
| Biotechs Industry Average Movement | 6.8% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 272's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 272's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 244 | Krzysztof Kaczmarczyk | www.mabion.eu |
Mabion S.A., a biotechnology company, engages in the development of various biotech drugs based on monoclonal antibody technology in Poland. The company develops, produces, and sells medicines for the treatment of neoplastic, autoimmune, metabolic, and neurological diseases. Its products include MabionCD20 and MabionHER2.
Mabion S.A. Fundamentals Summary
| 272 fundamental statistics | |
|---|---|
| Market cap | €32.05m |
| Earnings (TTM) | €2.40m |
| Revenue (TTM) | €25.97m |
13.4x
P/E Ratio1.2x
P/S RatioIs 272 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 272 income statement (TTM) | |
|---|---|
| Revenue | zł110.79m |
| Cost of Revenue | zł24.05m |
| Gross Profit | zł86.74m |
| Other Expenses | zł76.50m |
| Earnings | zł10.24m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.63 |
| Gross Margin | 78.29% |
| Net Profit Margin | 9.24% |
| Debt/Equity Ratio | 0.2% |
How did 272 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 23:54 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Mabion S.A. is covered by 11 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kamil Kliszcz | Biuro maklerskie mBanku |
| Beata Szparaga-Wasniewska | Biuro maklerskie mBanku |
| Pawel Sugalski | ING Groep NV |